300841 Chengdu Kanghua Biological Products
- 51.61
- -0.71-1.36%
Chengdu Kanghua Biological Products News
Kanghua Biotech (300841): Technology goes overseas and continues to promote shareholding plans to help long-term development
Kanghua Biotech (300841): Steady growth of human diploid rabies vaccine, employee stock ownership plans demonstrate confidence in development
Kanghua Biology (300841): 2024H1 performance increased steadily, and human diploid wild seedlings were released as scheduled
Kanghua Biotech (300841): Sales of main products increased significantly in 24Q2, employee stock ownership plans are beneficial to long-term development
Kanghua Biotech (300841): Stable performance growth in 2023, sales of human diploid wild seedlings are worth looking forward to
Kanghua Biotech (300841): A year-on-year improvement on the down payment cost side of receiving the Noro vaccine overseas transfer agreement
Kanghua Biology (300841): Noro vaccine is progressing smoothly in overseas diploid rabies vaccine continues to grow
Kanghua Biotech (300841) 2023 and 24Q1 Quarterly Report: Noro Vaccine Goes Overseas, Diploid Rabies Vaccine Continues to Grow
Kanghua Biotech (300841): Continued improvement in performance, significant increase in shareholder dividends
Kanghua Biotech (300841): Norovirus vaccine, a leading company in human diploidy vaccine, successfully launched overseas
Kanghua Biotech (300841) Review Report: Human rabies vaccine penetration rate increases, norovirus vaccine enters FDA clinical trials
Kanghua Biology (300841): Human diploid seedlings maintain rigidity and focus on the progress of hexavalent
Kanghua Biotech (300841): Short-term performance is under pressure and is optimistic about the progress of the hexavalent noro vaccine
Kanghua Biotech (300841): Significant improvement in sales repayment, increased R&D investment to create innovative vaccines
Kanghua Biotech (300841): Continuing to promote terminal sales and increase investment in R&D platforms
Kanghua Biotech (300841): Q2 delivery of human diploid seedlings has declined, R&D investment has increased, and profit performance has been affected
Kanghua Biotech (300841) 2023H1 review: The demand for human diploid seedlings is rigid, six-valent, and Phase I is being launched
Kanghua Biotech (300841): Steady revenue growth is expected to resume throughout the year
Kanghua Biology (300841): Human diploid vaccine maintains steady growth, increases R&D investment and expands multi-technology platforms
Kanghua Biotech (300841): Steady growth in the main business can be expected in 23 years
No Data
